Table 3.

Logistic regression analysis of clinical characteristics related to pathologic complete response (pCR) after neoadjuvant chemotherapy in young breast cancer patients.

Patient characteristic	Univariate analysis			Multivariate analysis
	OR	95% CI	P -value	OR	95% CI	P -value
Clinical stage			<0.001
I	1
II	1.701	0.828–3.493	0.148
III	1.081	0.516–2.246	0.836
Clinical T stage			<0.001			<0.001
cT1	1			1
cT2	0.864	0.616–1.212	0.398	0.759	0.532–1.081	0.127
cT3	0.457	0.298–0.701	<0.001	0.387	0.248–0.606	<0.001
cT4	0.459	0.246–0.859	0.015	0.378	0.197–0.722	0.003
Clinical N stage			0.629
cN0	1
cN1	0.999	0.776–1.287	0.996
cN2	0.957	0.640–1.431	0.83
cN3	0.724	0.435–1.205	0.214
Histological subtype			0.043
Ductal	1
Lobular	0.236	0.031–1.780	0.161
Mixed	0.472	0.109–2.054	0.317
Other	1.538	1.053–2.246	0.026
Molecular subtype			<0.001			<0.001
HR-/HER2+	1			1
HR+/HER2+	0.765	0.533–1.098	0.146	0.712	0.487–1.040	0.079
TNBC	1.283	0.900–1.829	0.169	1.337	0.871–2.053	0.185
Luminal A (HR+/HER2-, Ki67 < 20%)	0.184	0.092–0.370	<0.001	0.334	0.154–0.722	0.005
Luminal B (HR+/HER2-, Ki67≥20%)	0.523	0.372–0.735	<0.001	0.644	0.427–0.972	0.036
Neoadjuvant chemotherapy plan			<0.001			0.002
TAC/AC-T/TA	1			1
TC/TX/TP/AC	1.062	0.654–1.725	0.806	1.029	0.620–1.708	0.913
AC-TH/TCbH	1.461	1.022–2.089	0.037	1.456	0.934–2.270	0.098
TCbHP/THP/AC-THP	3.001	1.956–4.604	<0.001	2.900	1.744–4.821	<0.001
Other	1.285	0.903–1.829	0.163	1.344	0.913–1.979	0.134
Chemotherapy cycle			<0.001			<0.001
4	1			1
6/8	2.51	1.693–3.720	<0.001	2.558	1.699–3.853	<0.001
>8	2.914	1.715–4.953	<0.001	2.900	1.676–5.108	<0.001
Other	1.555	0.894–2.705	0.118	1.547	0.875–2.736	0.133
Ki-67, %	1.015	1.011–1.020	<0.001	1.011	1.005–1.017	<0.001

HER2, human epidermal growth factor receptor 2; TNBC, triple negative, negative for ER, PR and HER2; T, Docetaxel; H, Herceptin; X, Capecitabine; P, Carboplatin; A, Doxorubicin; C, Cyclophosphamide; Cb, Carboplatin; P, Pertuzumab.